Adverum Biotechnologies Inc. (ADVM), a clinical-stage company developing a gene therapy for highly prevalent ocular diseases, has a clinical trial catalyst lined up for this week.
The company's lead gene therapy candidate is Ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022, a one-time, intravitreal injection for patients with neovascular or wet age-related macular degeneration.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com